Department of Internal Medicine, Division of Metabolism and Endocrinology, St. Marianna University School of Medicine , Kawasaki, Japan.
Diabetes Technol Ther. 2013 Jul;15(7):550-5. doi: 10.1089/dia.2012.0334. Epub 2013 Apr 26.
Many diabetes patients who require insulin perform multiple subcutaneous injections every day that often cause pain, discomfort, and anxiety. We compared efficacy (glycemic control) and patient preference for two types of needle: a shorter straight needle (32 gauge×4 mm, straight wall; Nippon Becton Dickinson Co., Ltd., Tokyo, Japan; hereafter referred to as BD32S4) and a thinner microtapered needle (33-gauge tip and 28-gauge base×5 mm, double-tapered wall; Terumo Corp., Tokyo, Japan; hereafter referred to as TR33T5) in a single-center study.
Eighty-four patients with diabetes were enrolled in a randomized, open-label crossover trial. The patients injected their usual insulin dosage with one type of needle for 4 weeks and then switched to the other type for the next 4 weeks. The serum glycated albumin level was measured before and after each 4-week period. Each patient assessed pain during injection on a 150-mm visual analog scale (VAS). Needle preference, perceptions of handling, and acceptance were assessed by the patients, who completed a questionnaire after using each type of needle for 4 weeks.
In total, 79 patients completed the study. There was no difference of glycemic control between the two needles. The mean VAS score was -14.5 mm (95% confidence interval, -20.9, -8.0 mm), indicating that the patients perceived less pain with the BD32S4 needle. In the overall evaluation, a significantly higher percentage of patients selected the BD32S4 as the better needle compared with the TR33T5 (60.3% vs. 19.2%; P<0.0001).
The BD32S4 needle was more highly evaluated and was preferred by the patients with respect to pain during injection, usability, and visual impression, without having a negative impact on glycemic control. The overall preference of patients for the shorter needle in this study suggests that needle length may be one of the major contributing factors for patients' comfort in insulin injection, although the other relevant factors of needles still need to be considered.
许多需要胰岛素的糖尿病患者每天需要进行多次皮下注射,这常常会引起疼痛、不适和焦虑。我们比较了两种针的疗效(血糖控制)和患者偏好:一种是较短的直针(32 号×4 毫米,直壁;日本尼普顿·贝顿·迪金森公司;以下简称 BD32S4)和一种更细的微锥度针(33 号针尖和 28 号底座×5 毫米,双锥度壁;日本特鲁姆公司;以下简称 TR33T5)在一项单中心研究中。
84 名糖尿病患者参加了一项随机、开放标签的交叉试验。患者用一种类型的针注射其常规胰岛素剂量,持续 4 周,然后在接下来的 4 周内切换到另一种类型的针。在每 4 周结束时测量血清糖化白蛋白水平。每位患者在注射时使用 150 毫米视觉模拟量表(VAS)评估疼痛。在使用每种类型的针 4 周后,患者通过问卷评估对针的偏好、操作感和接受程度。
共有 79 名患者完成了这项研究。两种针的血糖控制没有差异。平均 VAS 评分为-14.5 毫米(95%置信区间,-20.9,-8.0 毫米),表明患者使用 BD32S4 针时疼痛感知较低。在总体评估中,选择 BD32S4 作为更好的针的患者比例明显高于选择 TR33T5 的患者(60.3%比 19.2%;P<0.0001)。
BD32S4 针在注射疼痛、可用性和视觉印象方面得到了更高的评价,并且更受患者的喜爱,而对血糖控制没有负面影响。在这项研究中,患者对较短针的总体偏好表明,针的长度可能是患者在胰岛素注射中舒适度的一个主要因素,尽管仍需要考虑其他相关因素。